{"success":true,"data":{"pressRelease":{"id":"129557","rtpr_id":"nPn8y2g8fa","ticker":"2142","exchange":"HKEX","all_tickers":["2142"],"title":"Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy","author":"PR Newswire","published_at":"2026-08-27T14:05:02.189Z","article_body":"Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy\n\nPR Newswire\n\nCAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2026\n\nCAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2026\n/PRNewswire/ -- Harbour BioMed (\"HBM\" or the \"Company\"; HKEX: 02142), a global\nbiopharmaceutical company committed to the discovery and development of novel\nantibody therapeutics in immunology, oncology and other areas, today announced\nits interim results for the six months ended June 30, 2026.\n\nDr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, commented:\n\"In the first half of 2026, Harbour BioMed continued to advance our Phase 3.0\nstrategy, with meaningful progress across all three integrated growth engines.\nWe continued to advance the global value of our mid- to late-stage innovative\nassets, further strengthened our technology platform capabilities,\nparticularly in AI-driven next-generation antibody discovery capability, and\ncontinued to deepen long-term strategic partnerships with leading global\npharmaceutical companies. The three growth engines are mutually reinforcing,\ncreating stronger connections among our technology platforms, innovative\npipeline and global partnership network, and continuously translating these\ncapabilities into long-term value.\n\nWe also achieved a landmark milestone in intellectual property protection. Our\nhistoric and decisive victory in the U.S. patent litigation not only\nreaffirmed the validity of the intellectual property underlying our core\nantibody discovery platforms, but also demonstrated our firm commitment to\nprotecting our core innovations and building global competitive advantages.\n\nIn terms of talent and organizational development, we have further streamlined\nour global management and scientific teams over the past six months. We have\nappointed experienced industry leaders, experts across multiple therapeutic\nareas, and world-renowned scientific advisors, who provide enhanced support\nfor R&D innovation, portfolio strategy, and global collaboration.\n\nLooking ahead, we will continue to drive strategic execution across our three\nintegrated growth engines, accelerate the advancement of high-potential\ninnovative assets into mid- to late-stage clinical development, unlock the\nglobal value of our technology platforms and pipeline, and further expand\nhigh-quality global partnerships. We are steadily advancing toward our 2028\nvision of becoming a globally leading platform-based biopharmaceutical group.\"\n\n2026 Interim Financial Highlights: Strong Revenue Growth and Sustained\nProfitability for Seven Consecutive Half-Years\n\n * Total revenue reached US$122.5 million, representing a 20.9% year-over-year\nincrease, primarily driven by continued strategic collaborations with global\nmultinational pharmaceutical companies, newly established out-licensing\nagreements for innovative products, and strong business growth of Nona\nBiosciences;\n * Profit for the period reached US$64.9 million, and adjusted net profit for the\nperiod([1]) was approximately US$71.6 million, marking seven consecutive\nprofitable half-years and confirming that Harbour BioMed has officially\nentered a phase of \"normalized profitability,\" further validating the\nsustainability and replicability of the business model underpinning this\nplatform-based biopharmaceutical group;\n * Cash and cash equivalents stood at approximately US$359.2 million as of June\n30, 2026. The Company maintains strong financial resources and flexibility to\nsupport its strategic execution.\n[1] Adjusted items of profit are mainly from share-based compensation expenses\nand other one-time expenses.\n\nMultiple Milestones Achieved, Unlocking the Global Value of Mid- to Late-Stage\nInnovative Assets\n\nHarbour BioMed continued to advance a differentiated portfolio across\nimmunology, oncology, obesity and metabolic diseases, and central nervous\nsystem (CNS) disorders, with multiple high-potential programs progressing\ntoward key clinical development milestones.\n\nKey programs in mid- to late-stage clinical development\n\nBatoclimab (HBM9161) is the first anti-FcRn monoclonal antibody to have\ncompleted Phase I to pivotal trials in China. The Biologics License\nApplication (BLA) for the treatment of generalized myasthenia gravis (gMG) was\naccepted by China's National Medical Products Administration (NMPA) in July\n2024 and is currently under review. Batoclimab has the potential to be a\nbreakthrough treatment option for a wide range of autoimmune diseases.\n\nHBM9378 is an ultra-long-acting fully human monoclonal antibody against TSLP\ngenerated from the H2L2 Harbour Mice(®) platform, engineered to achieve an\nextended half-life and effector silencing with subcutaneous administration. In\nMarch 2026, the Company published first-in-human Phase I trial results in the\npeer-reviewed journal Drug Design, Development and Therapy, demonstrating\nfavorable safety and an extended half-life (mean T1/2: 55.0–65.8 days).\n\nIn January 2025, it was announced that the Company and Kelun-Biotech entered\ninto an exclusive license agreement with Windward Bio, under which Windward\nBio was granted an exclusive license for the research, development,\nmanufacturing and commercialization of HBM9378 globally (excluding Greater\nChina and several Southeast and West Asian countries). In July 2025, our\npartner Windward Bio launched the Phase II/III POLARIS clinical study in\nasthma, with initial data expected in the second half of 2026 and the first\nPhase III study of HBM9378 in asthma is expected to begin in the fourth\nquarter of 2026. In June 2026, Windward Bio dosed the first patients in the\nPhase II SIRIUS study in COPD.\n\nNote: HBM9378 is known as SKB378 in Kelun-Biotech's pipeline and WIN378 in\nWindward Bio's pipeline.\n\nPorustobart (HBM4003) is a next-generation, fully human heavy-chain-only\nanti-CTLA-4 antibody discovered and developed using the HCAb Harbour Mice(®)\nplatform. It is also the first fully human heavy-chain-only antibody which\nentered clinical development globally. In October 2025, the Company published\npositive Phase II data in combination with tislelizumab for the treatment of\nmicrosatellite stable (MSS) metastatic colorectal cancer (mCRC). Of the 23\nevaluable patients, the objective response rate (ORR) is 34.8%, disease\ncontrol rate (DCR) is 60.9%, and 12-month overall survival (OS) Rate is 84%.\nIn February 2026, the Company entered a license agreement and equity\npartnership with Solstice Oncology, a clinical stage biotechnology company\nestablished by a syndicate of major venture capital investors, for the\nexclusive development and commercialization of HBM4003 outside Greater China.\nFollowing this agreement, HBM4003 made meaningful global development progress\nduring the reporting period.\n\nHBM7575 is an ultra-long-acting bispecific antibody targeting TSLP and an\nundisclosed antigen, with a dual mechanism of action. On one hand, by blocking\nthe interaction between TSLP and its receptor, it inhibits TSLP-mediated\nsignaling pathways and the activation of Th2 immune cells. On the other hand,\nbinding to and blocking the undisclosed target generates a synergistic effect,\nwith the potential to achieve broader control of inflammation compared to\nsingle-target approaches. HBM7575 has been engineered to allow for longer\ndosing intervals and a convenient subcutaneous route of administration. Based\non preclinical half-life data, the anticipated human half-life is expected to\nsupport dosing intervals of more than three months, positioning it as a\npotential best-in-class therapy.\n\nIn March 2026, an IND application for HBM7575 for the treatment of atopic\ndermatitis was approved by the NMPA, and the first participant has been dosed\nin a Phase 1 clinical study. In July 2026, an IND application for HBM7575 for\nthe treatment of asthma was approved by the NMPA.\n\nNote: HBM7575 is known as SKB575 in Kelun-Biotech's pipeline. According to the\ncollaboration agreement between Harbour BioMed and Kelun-Biotech, HBM7575 is\nled by Kelun-Biotech in its design, global development and commercialization,\nwith Harbour BioMed participating in the investment and development of this\nasset and sharing the benefits as agreed.\n\nKey products in the next-generation innovation portfolio include:\n\nHBM2001 is a potent TL1A×IL-23p19 bispecific antibody generated using the\nproprietary HBICA(®) bispecific technology and Harbour Mice(®) platform,\noffering a differentiated mechanism to address both inflammatory and fibrotic\npathways in inflammatory bowel disease. In April 2026, HBM2001 obtained FDA\nIND clearance to commence a Phase I trial in the United States. In July 2026,\nHBM2001 obtained NMPA IND clearance to commence a Phase I trial in China.\n\nHBM7020 is a BCMA×CD3 bispecific antibody generated using the HBICE(®)\ntechnology and Harbour Mice(®) platform. Following the global strategic\ncollaboration with Otsuka Pharmaceutical established in June 2025, HBM7020\ncontinued to advance product development as planned during the reporting\nperiod, with the Phase I clinical trial expected to initiate overseas in the\nsecond half of the year.\n\nHBM7004 is a novel B7H4×CD3 bispecific antibody demonstrating strong\nanti-tumor efficacy and favorable safety in preclinical studies. In May 2026,\nthe FDA cleared the IND application for HBM7004, enabling the initiation of a\nfirst-in-human Phase I clinical trial in the United States. In August 2026,\nthe NMPA approved the IND application for HBM7004 for the treatment of\nadvanced solid tumors.\n\nLET003 is the first ACVR2A/2B dual-target blocking antibody developed using\nthe Hu-mAtrIx™ artificial intelligence platform. ACVR2A and ACVR2B play\ncritical roles in regulating muscle-fat metabolic homeostasis. Extensive\npreclinical and clinical studies have demonstrated that combining\nreceptor-blocking antibodies targeting ACVR2A/2B with GLP-1-based weight loss\ntherapies can further reduce body fat while effectively mitigating lean mass\nloss. In May 2026, the Company announced promising preclinical data for\nLET003. Data showed that LET003 exhibited superior pharmacokinetic\ncharacteristics compared to multiple competitor molecules. When combined with\nsemaglutide, LET003 significantly enhanced fat reduction while effectively\npreserving lean mass. In addition, LET003 achieved lean mass-promoting effects\nat lower dose level comparable to bimagrumab at higher dose level,\nhighlighting its potential to become a best-in-class therapy for obesity\ntreatment. LET003 has advanced to the IND-enabling stage, with an IND\nsubmission expected in the third quarter of 2026.\n\nCNS Disease Programs: the Company is advancing a next-generation CNS pipeline\nfocused on Alzheimer's disease, Parkinson's disease, and other\nneurodegenerative disorders. Multiple programs are in preclinical development,\nwith NEU2005 expected to file an IND application in the first half of 2027.\n\nHBM9013 (CRH Neutralizing Antibody): HBM9013/HAT001 is a potent and selective\nanti-CRH neutralizing antibody for various disorders including congenital\nadrenal hyperplasia (CAH). In February 2025, HBM Alpha Therapeutics (HBMAT),\nan innovative biotechnology company incubated by the Company, announced a\nstrategic collaboration and license agreement with Spruce Biosciences. Under\nthe agreement, Spruce Biosciences gains exclusive global rights, excluding\nGreater China (mainland China, Taiwan, Hong Kong, and Macau), to develop and\ncommercialize HBM9013/HAT001.\n\nAI-Driven Next-Generation R&D Infrastructure Continues to Enhance\nInnovation Efficiency\n\nTechnology platform innovation remains a core pillar of Harbour BioMed's\nlong-term strategy. The Company continues to integrate its Hu-mAtrIx™ AI\nplatform with core antibody technology platforms including Harbour Mice(®),\nfurther embedding AI capabilities across the antibody drug discovery and\ndevelopment process to enhance R&D efficiency. The Company has established\na technology platform matrix spanning a broad range of therapeutic modalities,\nincluding bispecific and multi-specific antibodies, T-cell engagers (TCEs),\nantibody-drug conjugates (ADCs) and more, providing technological support for\nthe development of innovative therapies across multiple therapeutic areas.\n\nDuring the Reporting Period, the Company continued to enhance the Hu-mAtrIx™\nAI platform, strengthening capabilities including a fully human\nheavy-chain-only antibody model based on large-scale next-generation\nsequencing (NGS) HCAb sequence data, de novo design model, developability\nprediction, in silico screening and AI-guided engineering. The Company also\ncontinued to integrate AI with wet-lab experimental validation to explore more\nefficient approaches to drug discovery and development.\n\nAI-enabled R&D capabilities are increasingly translating into tangible\ninnovation. In May 2026, the Company announced positive preclinical data for\nLET003, its first next-generation candidate developed using the Hu-mAtrIx™\nAI platform. The results showed promising pharmacokinetic characteristics,\nwhile combination with semaglutide significantly enhanced fat reduction and\neffectively preserved lean mass, highlighting its potential to become a\nbest-in-class therapy for obesity.\n\nBuilding on these capabilities, the Company is also exploring new R&D\nmodels powered by AI. In June 2026, Harbour BioMed entered into a long-term\nglobal strategic partnership with BioMap and jointly initiated MegaStream\nTechBio, focused on AI-driven discovery and development of complex biologics.\nMegaStream will integrate proprietary datasets, purpose-built large models,\ninnovative pipeline assets and an intelligent dry-wet closed-loop R&D\nplatform, further advancing AI-enabled discovery and development of\nnext-generation complex biologics.\n\nDeepening Long-Term Platform-Based Strategic Partnerships to Expand the Global\nInnovation Ecosystem\n\nLeveraging its differentiated technology platforms and R&D capabilities,\nHarbour BioMed continued to establish multi-level partnerships with leading\nglobal pharmaceutical companies and biotechnology companies, and through\ndiversified collaboration models including strategic collaboration,\nco-development, product licensing, technology licensing and technology\nservices, has built a complete R&D chain spanning early discovery,\nclinical development and commercialization.\n\nIn December 2025, the Company entered into global strategic collaboration and\nlicense agreement with Bristol Myers Squibb (BMS) to discover and develop\nnext-generation multi-specific antibodies. Under the terms of the agreement,\nHarbour BioMed could receive payments totaling $90 million, as well as\ndevelopment and commercial milestones of up to $1.035 billion, along with\ntiered royalties should BMS elect to advance all potential programs.\n\nIn the first half of 2026, the Company entered into a license agreement and\nequity partnership with Solstice Oncology for HBM4003. Under the terms of the\nagreement, the Company received upfront consideration valued at over $105\nmillion and is eligible for additional development, regulatory and commercial\nmilestones up to approximately $1.1 billion, plus tiered royalties on net\nsales outside Greater China. The Company also participated in Windward Bio's\nUS$165 million financing and continued to deepen collaboration with global\npartners in antibody discovery, CNS delivery and other innovative areas.\n\nAdditionally, Nona Biosciences, the wholly owned subsidiary of Harbour BioMed,\nentered into a multi-target antibody discovery collaboration with Link Cell\nTherapies in January 2026, leveraging Nona's proprietary fully human HCAb\nHarbour Mice(®) platform and its innovative direct CAR-function-based HCAb\nlibrary screening platform, NonaCarFx™, to generate novel CAR-T cell therapy\ncandidates.\n\nIn June 2026, Nona Biosciences entered into a strategic collaboration with\nLonza. This collaboration leverages Nona's proprietary Harbour Mice(®) fully\nhuman HCAb platform to discover and develop next-generation single-domain\nantibody-based blood-brain barrier (BBB)-crossing technologies. Leveraging the\nplatform's proven ability to generate fully human HCAbs and VHH binders with\nexceptional affinity and developability, the partnership aims to establish a\nbest-in-class BBB-crossing technology capable of enabling the delivery of a\ndiverse range of therapeutic modalities into the central nervous system (CNS)\nand unlocking new opportunities in CNS drug development and technology\nlicensing. Under the terms of the agreement, Nona is entitled to receive\nupfront and option payments from Lonza. The parties will also share revenues\ngenerated from future licensing agreements pursuant to the collaboration.\n\nThis multi-level approach creates a resilient, scalable business model\ndesigned to generate long-term, predictable value.\n\nContinuously Strengthening Innovation and Intellectual Property Barriers,\nFurther Enhancing Global Team Capabilities\n\nAlongside continued progress in pipeline development and business\ncollaborations, Harbour BioMed further strengthened the technology,\nintellectual property and talent foundation supporting its long-term\ninnovation.\n\nAs of June 30, 2026, the Company had filed 706 patent applications, including\n19 invention patents granted by the China National Intellectual Property\nAdministration, with 521 patent applications under review. At the same time,\nthe Company continued to strengthen its global management and scientific team\nby bringing together experienced industry leaders, experts across multiple\ntherapeutic areas, and world-renowned scientific advisors, further enhancing\nits professional capabilities in R&D innovation, asset strategy, external\ninnovation and global collaboration.\n\nDuring the Reporting Period, the Company achieved a decisive victory in its\ncore U.S. patent litigation. The jury upheld the validity of the relevant core\npatent, found Amgen's infringement to be willful and awarded Harbour BioMed\nUS$20.20 million in damages – the full amount requested. The findings of\nwillful infringement also entitle the Company to petition the judge to treble\nthe award, potentially increasing the award to up to $60.6 million. The\nverdict further validated the validity and enforceability of the intellectual\nproperty underlying the Company's core antibody discovery platform and\nprovided important support for the Company's continued expansion of global\ncollaborations and platform value.\n\nAccelerating 2026 Strategic Execution Toward the 2028 Vision\n\nLooking ahead, Harbour BioMed will continue to drive business growth through\nits three integrated growth engines and steadily advance toward its 2028\nvision of becoming a globally leading platform-based biopharmaceutical group.\n\nIn the second half of 2026, the Company expects to advance multiple\nhigh-potential programs toward key clinical milestones, including the initial\ndata readout from the Phase II/III POLARIS study of HBM9378/WIN378, as well as\npotential significant milestones for porustobart (HBM4003). The Company will\nalso continue to accelerate next-generation innovative candidates into\nclinical development and advance its differentiated pipeline across\nimmunology, oncology, obesity and metabolic diseases, and central nervous\nsystem disorders. Additionally, the Company will actively explore diverse\ncollaboration opportunities and further strengthen its position in the global\ninnovation ecosystem by expanding strategic partnerships with global partners,\ncontinuing to bring transformative biotherapeutics to patients worldwide.\n\nAbout Harbour BioMed\n\nHarbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed\nto the discovery and development of novel antibody therapeutics in immunology,\noncology and other areas. The Company is building a robust portfolio and\ndifferentiated pipeline through internal R&D capability, strategic global\ncollaborations in co-discovery and co-development, and selective acquisitions.\n\nOur proprietary antibody technology platform, Harbour Mice(®), generates\nfully human monoclonal antibodies in both the conventional two heavy and two\nlight chain (H2L2) format and the heavy chain-only (HCAb) format. Building\nupon HCAb antibodies, the HCAb-based immune cell engagers (HBICE(®))\nbispecific antibody technology enables tumor-killing effects that traditional\ncombination therapies cannot achieve. The HCAb-based Antibody Plus technology\n(HCAb PLUS(TM)) provides comprehensive modality solutions for the development\nof innovative multi-specific medicines in different disease areas.\nAdditionally, building upon the Harbour Mice(®) platform, Harbour BioMed\nlaunched its first fully human Generative AI HCAb Model powered by its\nHu-mAtrIx(TM) AI platform, accelerating the development of innovative\ntherapies.\n\nBy integrating Harbour Mice(®), HBICE(®), HCAb PLUS(TM), a single B-cell\ncloning platform and AI technologies, Harbour BioMed has built a highly\nefficient and distinctive antibody discovery engine for developing\nnext-generation therapeutic antibodies. For more information, please\nvisit www.harbourbiomed.com (https://www.harbourbiomed.com/) .\n\n \n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/harbour-biomed-reports-2026-interim-results-three-integrated-growth-engines-accelerate-execution-of-its-platform-based-strategy-302861906.html\n(https://www.prnewswire.com/news-releases/harbour-biomed-reports-2026-interim-results-three-integrated-growth-engines-accelerate-execution-of-its-platform-based-strategy-302861906.html)\n\nSOURCE Harbour BioMed\n\n\n\nMaKathy, kathy.ma@harbourbiomed.com, +86-13681792070\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1199639/HB-Logo.jpg?id=OA2909589\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn8y2g8fa","title":"Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy","author":"PR Newswire","ticker":"2142","created":"2026-08-27T14:05:02.189Z","tickers":["2142"],"exchange":"HKEX","article_body":"Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy\n\nPR Newswire\n\nCAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2026\n\nCAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2026\n/PRNewswire/ -- Harbour BioMed (\"HBM\" or the \"Company\"; HKEX: 02142), a global\nbiopharmaceutical company committed to the discovery and development of novel\nantibody therapeutics in immunology, oncology and other areas, today announced\nits interim results for the six months ended June 30, 2026.\n\nDr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, commented:\n\"In the first half of 2026, Harbour BioMed continued to advance our Phase 3.0\nstrategy, with meaningful progress across all three integrated growth engines.\nWe continued to advance the global value of our mid- to late-stage innovative\nassets, further strengthened our technology platform capabilities,\nparticularly in AI-driven next-generation antibody discovery capability, and\ncontinued to deepen long-term strategic partnerships with leading global\npharmaceutical companies. The three growth engines are mutually reinforcing,\ncreating stronger connections among our technology platforms, innovative\npipeline and global partnership network, and continuously translating these\ncapabilities into long-term value.\n\nWe also achieved a landmark milestone in intellectual property protection. Our\nhistoric and decisive victory in the U.S. patent litigation not only\nreaffirmed the validity of the intellectual property underlying our core\nantibody discovery platforms, but also demonstrated our firm commitment to\nprotecting our core innovations and building global competitive advantages.\n\nIn terms of talent and organizational development, we have further streamlined\nour global management and scientific teams over the past six months. We have\nappointed experienced industry leaders, experts across multiple therapeutic\nareas, and world-renowned scientific advisors, who provide enhanced support\nfor R&D innovation, portfolio strategy, and global collaboration.\n\nLooking ahead, we will continue to drive strategic execution across our three\nintegrated growth engines, accelerate the advancement of high-potential\ninnovative assets into mid- to late-stage clinical development, unlock the\nglobal value of our technology platforms and pipeline, and further expand\nhigh-quality global partnerships. We are steadily advancing toward our 2028\nvision of becoming a globally leading platform-based biopharmaceutical group.\"\n\n2026 Interim Financial Highlights: Strong Revenue Growth and Sustained\nProfitability for Seven Consecutive Half-Years\n\n * Total revenue reached US$122.5 million, representing a 20.9% year-over-year\nincrease, primarily driven by continued strategic collaborations with global\nmultinational pharmaceutical companies, newly established out-licensing\nagreements for innovative products, and strong business growth of Nona\nBiosciences;\n * Profit for the period reached US$64.9 million, and adjusted net profit for the\nperiod([1]) was approximately US$71.6 million, marking seven consecutive\nprofitable half-years and confirming that Harbour BioMed has officially\nentered a phase of \"normalized profitability,\" further validating the\nsustainability and replicability of the business model underpinning this\nplatform-based biopharmaceutical group;\n * Cash and cash equivalents stood at approximately US$359.2 million as of June\n30, 2026. The Company maintains strong financial resources and flexibility to\nsupport its strategic execution.\n[1] Adjusted items of profit are mainly from share-based compensation expenses\nand other one-time expenses.\n\nMultiple Milestones Achieved, Unlocking the Global Value of Mid- to Late-Stage\nInnovative Assets\n\nHarbour BioMed continued to advance a differentiated portfolio across\nimmunology, oncology, obesity and metabolic diseases, and central nervous\nsystem (CNS) disorders, with multiple high-potential programs progressing\ntoward key clinical development milestones.\n\nKey programs in mid- to late-stage clinical development\n\nBatoclimab (HBM9161) is the first anti-FcRn monoclonal antibody to have\ncompleted Phase I to pivotal trials in China. The Biologics License\nApplication (BLA) for the treatment of generalized myasthenia gravis (gMG) was\naccepted by China's National Medical Products Administration (NMPA) in July\n2024 and is currently under review. Batoclimab has the potential to be a\nbreakthrough treatment option for a wide range of autoimmune diseases.\n\nHBM9378 is an ultra-long-acting fully human monoclonal antibody against TSLP\ngenerated from the H2L2 Harbour Mice(®) platform, engineered to achieve an\nextended half-life and effector silencing with subcutaneous administration. In\nMarch 2026, the Company published first-in-human Phase I trial results in the\npeer-reviewed journal Drug Design, Development and Therapy, demonstrating\nfavorable safety and an extended half-life (mean T1/2: 55.0–65.8 days).\n\nIn January 2025, it was announced that the Company and Kelun-Biotech entered\ninto an exclusive license agreement with Windward Bio, under which Windward\nBio was granted an exclusive license for the research, development,\nmanufacturing and commercialization of HBM9378 globally (excluding Greater\nChina and several Southeast and West Asian countries). In July 2025, our\npartner Windward Bio launched the Phase II/III POLARIS clinical study in\nasthma, with initial data expected in the second half of 2026 and the first\nPhase III study of HBM9378 in asthma is expected to begin in the fourth\nquarter of 2026. In June 2026, Windward Bio dosed the first patients in the\nPhase II SIRIUS study in COPD.\n\nNote: HBM9378 is known as SKB378 in Kelun-Biotech's pipeline and WIN378 in\nWindward Bio's pipeline.\n\nPorustobart (HBM4003) is a next-generation, fully human heavy-chain-only\nanti-CTLA-4 antibody discovered and developed using the HCAb Harbour Mice(®)\nplatform. It is also the first fully human heavy-chain-only antibody which\nentered clinical development globally. In October 2025, the Company published\npositive Phase II data in combination with tislelizumab for the treatment of\nmicrosatellite stable (MSS) metastatic colorectal cancer (mCRC). Of the 23\nevaluable patients, the objective response rate (ORR) is 34.8%, disease\ncontrol rate (DCR) is 60.9%, and 12-month overall survival (OS) Rate is 84%.\nIn February 2026, the Company entered a license agreement and equity\npartnership with Solstice Oncology, a clinical stage biotechnology company\nestablished by a syndicate of major venture capital investors, for the\nexclusive development and commercialization of HBM4003 outside Greater China.\nFollowing this agreement, HBM4003 made meaningful global development progress\nduring the reporting period.\n\nHBM7575 is an ultra-long-acting bispecific antibody targeting TSLP and an\nundisclosed antigen, with a dual mechanism of action. On one hand, by blocking\nthe interaction between TSLP and its receptor, it inhibits TSLP-mediated\nsignaling pathways and the activation of Th2 immune cells. On the other hand,\nbinding to and blocking the undisclosed target generates a synergistic effect,\nwith the potential to achieve broader control of inflammation compared to\nsingle-target approaches. HBM7575 has been engineered to allow for longer\ndosing intervals and a convenient subcutaneous route of administration. Based\non preclinical half-life data, the anticipated human half-life is expected to\nsupport dosing intervals of more than three months, positioning it as a\npotential best-in-class therapy.\n\nIn March 2026, an IND application for HBM7575 for the treatment of atopic\ndermatitis was approved by the NMPA, and the first participant has been dosed\nin a Phase 1 clinical study. In July 2026, an IND application for HBM7575 for\nthe treatment of asthma was approved by the NMPA.\n\nNote: HBM7575 is known as SKB575 in Kelun-Biotech's pipeline. According to the\ncollaboration agreement between Harbour BioMed and Kelun-Biotech, HBM7575 is\nled by Kelun-Biotech in its design, global development and commercialization,\nwith Harbour BioMed participating in the investment and development of this\nasset and sharing the benefits as agreed.\n\nKey products in the next-generation innovation portfolio include:\n\nHBM2001 is a potent TL1A×IL-23p19 bispecific antibody generated using the\nproprietary HBICA(®) bispecific technology and Harbour Mice(®) platform,\noffering a differentiated mechanism to address both inflammatory and fibrotic\npathways in inflammatory bowel disease. In April 2026, HBM2001 obtained FDA\nIND clearance to commence a Phase I trial in the United States. In July 2026,\nHBM2001 obtained NMPA IND clearance to commence a Phase I trial in China.\n\nHBM7020 is a BCMA×CD3 bispecific antibody generated using the HBICE(®)\ntechnology and Harbour Mice(®) platform. Following the global strategic\ncollaboration with Otsuka Pharmaceutical established in June 2025, HBM7020\ncontinued to advance product development as planned during the reporting\nperiod, with the Phase I clinical trial expected to initiate overseas in the\nsecond half of the year.\n\nHBM7004 is a novel B7H4×CD3 bispecific antibody demonstrating strong\nanti-tumor efficacy and favorable safety in preclinical studies. In May 2026,\nthe FDA cleared the IND application for HBM7004, enabling the initiation of a\nfirst-in-human Phase I clinical trial in the United States. In August 2026,\nthe NMPA approved the IND application for HBM7004 for the treatment of\nadvanced solid tumors.\n\nLET003 is the first ACVR2A/2B dual-target blocking antibody developed using\nthe Hu-mAtrIx™ artificial intelligence platform. ACVR2A and ACVR2B play\ncritical roles in regulating muscle-fat metabolic homeostasis. Extensive\npreclinical and clinical studies have demonstrated that combining\nreceptor-blocking antibodies targeting ACVR2A/2B with GLP-1-based weight loss\ntherapies can further reduce body fat while effectively mitigating lean mass\nloss. In May 2026, the Company announced promising preclinical data for\nLET003. Data showed that LET003 exhibited superior pharmacokinetic\ncharacteristics compared to multiple competitor molecules. When combined with\nsemaglutide, LET003 significantly enhanced fat reduction while effectively\npreserving lean mass. In addition, LET003 achieved lean mass-promoting effects\nat lower dose level comparable to bimagrumab at higher dose level,\nhighlighting its potential to become a best-in-class therapy for obesity\ntreatment. LET003 has advanced to the IND-enabling stage, with an IND\nsubmission expected in the third quarter of 2026.\n\nCNS Disease Programs: the Company is advancing a next-generation CNS pipeline\nfocused on Alzheimer's disease, Parkinson's disease, and other\nneurodegenerative disorders. Multiple programs are in preclinical development,\nwith NEU2005 expected to file an IND application in the first half of 2027.\n\nHBM9013 (CRH Neutralizing Antibody): HBM9013/HAT001 is a potent and selective\nanti-CRH neutralizing antibody for various disorders including congenital\nadrenal hyperplasia (CAH). In February 2025, HBM Alpha Therapeutics (HBMAT),\nan innovative biotechnology company incubated by the Company, announced a\nstrategic collaboration and license agreement with Spruce Biosciences. Under\nthe agreement, Spruce Biosciences gains exclusive global rights, excluding\nGreater China (mainland China, Taiwan, Hong Kong, and Macau), to develop and\ncommercialize HBM9013/HAT001.\n\nAI-Driven Next-Generation R&D Infrastructure Continues to Enhance\nInnovation Efficiency\n\nTechnology platform innovation remains a core pillar of Harbour BioMed's\nlong-term strategy. The Company continues to integrate its Hu-mAtrIx™ AI\nplatform with core antibody technology platforms including Harbour Mice(®),\nfurther embedding AI capabilities across the antibody drug discovery and\ndevelopment process to enhance R&D efficiency. The Company has established\na technology platform matrix spanning a broad range of therapeutic modalities,\nincluding bispecific and multi-specific antibodies, T-cell engagers (TCEs),\nantibody-drug conjugates (ADCs) and more, providing technological support for\nthe development of innovative therapies across multiple therapeutic areas.\n\nDuring the Reporting Period, the Company continued to enhance the Hu-mAtrIx™\nAI platform, strengthening capabilities including a fully human\nheavy-chain-only antibody model based on large-scale next-generation\nsequencing (NGS) HCAb sequence data, de novo design model, developability\nprediction, in silico screening and AI-guided engineering. The Company also\ncontinued to integrate AI with wet-lab experimental validation to explore more\nefficient approaches to drug discovery and development.\n\nAI-enabled R&D capabilities are increasingly translating into tangible\ninnovation. In May 2026, the Company announced positive preclinical data for\nLET003, its first next-generation candidate developed using the Hu-mAtrIx™\nAI platform. The results showed promising pharmacokinetic characteristics,\nwhile combination with semaglutide significantly enhanced fat reduction and\neffectively preserved lean mass, highlighting its potential to become a\nbest-in-class therapy for obesity.\n\nBuilding on these capabilities, the Company is also exploring new R&D\nmodels powered by AI. In June 2026, Harbour BioMed entered into a long-term\nglobal strategic partnership with BioMap and jointly initiated MegaStream\nTechBio, focused on AI-driven discovery and development of complex biologics.\nMegaStream will integrate proprietary datasets, purpose-built large models,\ninnovative pipeline assets and an intelligent dry-wet closed-loop R&D\nplatform, further advancing AI-enabled discovery and development of\nnext-generation complex biologics.\n\nDeepening Long-Term Platform-Based Strategic Partnerships to Expand the Global\nInnovation Ecosystem\n\nLeveraging its differentiated technology platforms and R&D capabilities,\nHarbour BioMed continued to establish multi-level partnerships with leading\nglobal pharmaceutical companies and biotechnology companies, and through\ndiversified collaboration models including strategic collaboration,\nco-development, product licensing, technology licensing and technology\nservices, has built a complete R&D chain spanning early discovery,\nclinical development and commercialization.\n\nIn December 2025, the Company entered into global strategic collaboration and\nlicense agreement with Bristol Myers Squibb (BMS) to discover and develop\nnext-generation multi-specific antibodies. Under the terms of the agreement,\nHarbour BioMed could receive payments totaling $90 million, as well as\ndevelopment and commercial milestones of up to $1.035 billion, along with\ntiered royalties should BMS elect to advance all potential programs.\n\nIn the first half of 2026, the Company entered into a license agreement and\nequity partnership with Solstice Oncology for HBM4003. Under the terms of the\nagreement, the Company received upfront consideration valued at over $105\nmillion and is eligible for additional development, regulatory and commercial\nmilestones up to approximately $1.1 billion, plus tiered royalties on net\nsales outside Greater China. The Company also participated in Windward Bio's\nUS$165 million financing and continued to deepen collaboration with global\npartners in antibody discovery, CNS delivery and other innovative areas.\n\nAdditionally, Nona Biosciences, the wholly owned subsidiary of Harbour BioMed,\nentered into a multi-target antibody discovery collaboration with Link Cell\nTherapies in January 2026, leveraging Nona's proprietary fully human HCAb\nHarbour Mice(®) platform and its innovative direct CAR-function-based HCAb\nlibrary screening platform, NonaCarFx™, to generate novel CAR-T cell therapy\ncandidates.\n\nIn June 2026, Nona Biosciences entered into a strategic collaboration with\nLonza. This collaboration leverages Nona's proprietary Harbour Mice(®) fully\nhuman HCAb platform to discover and develop next-generation single-domain\nantibody-based blood-brain barrier (BBB)-crossing technologies. Leveraging the\nplatform's proven ability to generate fully human HCAbs and VHH binders with\nexceptional affinity and developability, the partnership aims to establish a\nbest-in-class BBB-crossing technology capable of enabling the delivery of a\ndiverse range of therapeutic modalities into the central nervous system (CNS)\nand unlocking new opportunities in CNS drug development and technology\nlicensing. Under the terms of the agreement, Nona is entitled to receive\nupfront and option payments from Lonza. The parties will also share revenues\ngenerated from future licensing agreements pursuant to the collaboration.\n\nThis multi-level approach creates a resilient, scalable business model\ndesigned to generate long-term, predictable value.\n\nContinuously Strengthening Innovation and Intellectual Property Barriers,\nFurther Enhancing Global Team Capabilities\n\nAlongside continued progress in pipeline development and business\ncollaborations, Harbour BioMed further strengthened the technology,\nintellectual property and talent foundation supporting its long-term\ninnovation.\n\nAs of June 30, 2026, the Company had filed 706 patent applications, including\n19 invention patents granted by the China National Intellectual Property\nAdministration, with 521 patent applications under review. At the same time,\nthe Company continued to strengthen its global management and scientific team\nby bringing together experienced industry leaders, experts across multiple\ntherapeutic areas, and world-renowned scientific advisors, further enhancing\nits professional capabilities in R&D innovation, asset strategy, external\ninnovation and global collaboration.\n\nDuring the Reporting Period, the Company achieved a decisive victory in its\ncore U.S. patent litigation. The jury upheld the validity of the relevant core\npatent, found Amgen's infringement to be willful and awarded Harbour BioMed\nUS$20.20 million in damages – the full amount requested. The findings of\nwillful infringement also entitle the Company to petition the judge to treble\nthe award, potentially increasing the award to up to $60.6 million. The\nverdict further validated the validity and enforceability of the intellectual\nproperty underlying the Company's core antibody discovery platform and\nprovided important support for the Company's continued expansion of global\ncollaborations and platform value.\n\nAccelerating 2026 Strategic Execution Toward the 2028 Vision\n\nLooking ahead, Harbour BioMed will continue to drive business growth through\nits three integrated growth engines and steadily advance toward its 2028\nvision of becoming a globally leading platform-based biopharmaceutical group.\n\nIn the second half of 2026, the Company expects to advance multiple\nhigh-potential programs toward key clinical milestones, including the initial\ndata readout from the Phase II/III POLARIS study of HBM9378/WIN378, as well as\npotential significant milestones for porustobart (HBM4003). The Company will\nalso continue to accelerate next-generation innovative candidates into\nclinical development and advance its differentiated pipeline across\nimmunology, oncology, obesity and metabolic diseases, and central nervous\nsystem disorders. Additionally, the Company will actively explore diverse\ncollaboration opportunities and further strengthen its position in the global\ninnovation ecosystem by expanding strategic partnerships with global partners,\ncontinuing to bring transformative biotherapeutics to patients worldwide.\n\nAbout Harbour BioMed\n\nHarbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed\nto the discovery and development of novel antibody therapeutics in immunology,\noncology and other areas. The Company is building a robust portfolio and\ndifferentiated pipeline through internal R&D capability, strategic global\ncollaborations in co-discovery and co-development, and selective acquisitions.\n\nOur proprietary antibody technology platform, Harbour Mice(®), generates\nfully human monoclonal antibodies in both the conventional two heavy and two\nlight chain (H2L2) format and the heavy chain-only (HCAb) format. Building\nupon HCAb antibodies, the HCAb-based immune cell engagers (HBICE(®))\nbispecific antibody technology enables tumor-killing effects that traditional\ncombination therapies cannot achieve. The HCAb-based Antibody Plus technology\n(HCAb PLUS(TM)) provides comprehensive modality solutions for the development\nof innovative multi-specific medicines in different disease areas.\nAdditionally, building upon the Harbour Mice(®) platform, Harbour BioMed\nlaunched its first fully human Generative AI HCAb Model powered by its\nHu-mAtrIx(TM) AI platform, accelerating the development of innovative\ntherapies.\n\nBy integrating Harbour Mice(®), HBICE(®), HCAb PLUS(TM), a single B-cell\ncloning platform and AI technologies, Harbour BioMed has built a highly\nefficient and distinctive antibody discovery engine for developing\nnext-generation therapeutic antibodies. For more information, please\nvisit www.harbourbiomed.com (https://www.harbourbiomed.com/) .\n\n \n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/harbour-biomed-reports-2026-interim-results-three-integrated-growth-engines-accelerate-execution-of-its-platform-based-strategy-302861906.html\n(https://www.prnewswire.com/news-releases/harbour-biomed-reports-2026-interim-results-three-integrated-growth-engines-accelerate-execution-of-its-platform-based-strategy-302861906.html)\n\nSOURCE Harbour BioMed\n\n\n\nMaKathy, kathy.ma@harbourbiomed.com, +86-13681792070\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1199639/HB-Logo.jpg?id=OA2909589\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-08-27T14:05:02.299919155Z","server_sent_at_ms":1787839502299},"received_at":"2026-08-27T14:05:02.449Z","source_url":"https://www.prnewswire.com/news-releases/harbour-biomed-reports-2026-interim-results-three-integrated-growth-engines-accelerate-execution-of-its-platform-based-strategy-302861906.html"},"analysis":{"id":"118471","press_release_id":"129557","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"earnings","narrative":"Harbour BioMed reported H1 2026 revenue of US$122.5 million, up 20.9% year-over-year, with profit reaching US$64.9 million and cash reserves of US$359.2 million, marking seven consecutive profitable half-years.\n\nThe company achieved a major legal victory against Amgen, with a jury finding willful infringement of Harbour's core patent and awarding US$20.20 million in damages, which could be trebled to US$60.6 million.\n\nStrategic partnerships advanced significantly, including a deal with Bristol Myers Squibb worth up to US$1.035 billion and a Solstice Oncology agreement for HBM4003 generating over US$105 million in upfront consideration.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Profitable growth and IP win vs Amgen validate Harbour BioMed's platform strategy."},"keyFigures":{"revenue":"US$122.5 million","revenueYoy":"20.9%","customDimensions":{"cash":"US$359.2 million","profit":"US$64.9 million","bms_milestones":"US$1.035 billion","adjusted_net_profit":"US$71.6 million","bms_upfront_payment":"US$90 million","solstice_milestones":"US$1.1 billion","patent_damages_awarded":"US$20.20 million","potential_treble_damages":"US$60.6 million","solstice_upfront_payment":"US$105 million"}},"quotedText":"In the first half of 2026, Harbour BioMed continued to advance our Phase 3.0 strategy, with meaningful progress across all three integrated growth engines.","namedEntities":{"people":[{"name":"Dr. Jingsong Wang","role":"Founder, Chairman, and CEO"}],"products":["Batoclimab","HBM9378","Porustobart","HBM4003","HBM7575","HBM2001","HBM7020","HBM7004","LET003","NEU2005","HBM9013","Harbour Mice"],"companies":[{"name":"Harbour BioMed","ticker":"2142"},{"name":"Amgen","ticker":"AMGN","relationship":"litigation opponent"},{"name":"Bristol Myers Squibb","ticker":"BMS","relationship":"partner"},{"name":"Lonza","ticker":"LON","relationship":"partner"},{"name":"Solstice Oncology","relationship":"partner"},{"name":"Windward Bio","relationship":"partner"},{"name":"BioMap","relationship":"partner"}],"dollarAmounts":[{"amount":"US$122.5 million","context":"Total revenue for six months ended June 30, 2026"},{"amount":"US$64.9 million","context":"Profit for the period"},{"amount":"US$359.2 million","context":"Cash and cash equivalents"},{"amount":"US$20.20 million","context":"Damages awarded by jury in patent litigation vs Amgen"},{"amount":"US$60.6 million","context":"Potential trebled damages in patent litigation"},{"amount":"US$90 million","context":"Upfront payments from Bristol Myers Squibb agreement"},{"amount":"US$1.035 billion","context":"Development and commercial milestones from Bristol Myers Squibb agreement"},{"amount":"US$105 million","context":"Upfront consideration from Solstice Oncology agreement"},{"amount":"US$1.1 billion","context":"Potential milestones from Solstice Oncology agreement"}]},"materialImpact":{"score":4,"reasoning":"Strong top-line growth of 20.9% and sustained profitability (7th consecutive half-year) combined with a major legal victory against Amgen validating core IP, plus significant partnership milestones with Bristol Myers Squibb and Solstice Oncology."},"tickerRelevance":{"others":[{"ticker":"BMS","relevance":"partner"},{"ticker":"AMGN","relevance":"litigation opponent"},{"ticker":"LON","relevance":"partner"}],"primary":"2142"},"globalImportance":25,"audienceRelevance":20,"eventTypeSecondary":["legal_litigation","partnership"],"importanceComponents":{"tickerTier":"mid_cap","eventGravity":"earnings_and_legal_win","sectorWeight":"biotech","householdBrandBoost":0}},"event_type":"earnings","event_type_secondary":["legal_litigation","partnership"],"sentiment":"bullish","material_impact_score":4,"narrative":"Harbour BioMed reported H1 2026 revenue of US$122.5 million, up 20.9% year-over-year, with profit reaching US$64.9 million and cash reserves of US$359.2 million, marking seven consecutive profitable half-years.\n\nThe company achieved a major legal victory against Amgen, with a jury finding willful infringement of Harbour's core patent and awarding US$20.20 million in damages, which could be trebled to US$60.6 million.\n\nStrategic partnerships advanced significantly, including a deal with Bristol Myers Squibb worth up to US$1.035 billion and a Solstice Oncology agreement for HBM4003 generating over US$105 million in upfront consideration.","key_figures":{"revenue":"US$122.5 million","revenueYoy":"20.9%","customDimensions":{"cash":"US$359.2 million","profit":"US$64.9 million","bms_milestones":"US$1.035 billion","adjusted_net_profit":"US$71.6 million","bms_upfront_payment":"US$90 million","solstice_milestones":"US$1.1 billion","patent_damages_awarded":"US$20.20 million","potential_treble_damages":"US$60.6 million","solstice_upfront_payment":"US$105 million"}},"named_entities":{"people":[{"name":"Dr. Jingsong Wang","role":"Founder, Chairman, and CEO"}],"products":["Batoclimab","HBM9378","Porustobart","HBM4003","HBM7575","HBM2001","HBM7020","HBM7004","LET003","NEU2005","HBM9013","Harbour Mice"],"companies":[{"name":"Harbour BioMed","ticker":"2142"},{"name":"Amgen","ticker":"AMGN","relationship":"litigation opponent"},{"name":"Bristol Myers Squibb","ticker":"BMS","relationship":"partner"},{"name":"Lonza","ticker":"LON","relationship":"partner"},{"name":"Solstice Oncology","relationship":"partner"},{"name":"Windward Bio","relationship":"partner"},{"name":"BioMap","relationship":"partner"}],"dollarAmounts":[{"amount":"US$122.5 million","context":"Total revenue for six months ended June 30, 2026"},{"amount":"US$64.9 million","context":"Profit for the period"},{"amount":"US$359.2 million","context":"Cash and cash equivalents"},{"amount":"US$20.20 million","context":"Damages awarded by jury in patent litigation vs Amgen"},{"amount":"US$60.6 million","context":"Potential trebled damages in patent litigation"},{"amount":"US$90 million","context":"Upfront payments from Bristol Myers Squibb agreement"},{"amount":"US$1.035 billion","context":"Development and commercial milestones from Bristol Myers Squibb agreement"},{"amount":"US$105 million","context":"Upfront consideration from Solstice Oncology agreement"},{"amount":"US$1.1 billion","context":"Potential milestones from Solstice Oncology agreement"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-27T15:55:38.219Z","global_importance":25,"audience_relevance":20,"importance_components":{"tickerTier":"mid_cap","eventGravity":"earnings_and_legal_win","sectorWeight":"biotech","householdBrandBoost":0}},"durationMs":246671,"modelName":"glm-4.7"}}